Clinical trials
Schizophrenia trials in Japan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
63 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 8 |
| 2011 | 3 |
| 2012 | 9 |
| 2013 | 1 |
| 2014 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 48 |
| Terminated | 8 |
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Otsuka Pharmaceutical Co., Ltd. | 10 |
| Sumitomo Pharma Co., Ltd. | 9 |
| Boehringer Ingelheim | 6 |
| Tanabe Pharma Corporation | 6 |
| Eli Lilly and Company | 5 |
| Hoffmann-La Roche | 5 |
| Janssen Pharmaceutical K.K. | 4 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 3 |
| Bristol-Myers Squibb | 2 |
| Denovo Biopharma LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Schizophrenia | 63 |
| Mental Disorders | 5 |
| Psychotic Disorders | 3 |
| Autistic Disorder | 1 |
| Bipolar Disorder | 1 |
| Cognition Disorders | 1 |
| Cognitive Dysfunction | 1 |
| Sleep Initiation and Maintenance Disorders | 1 |
Trials
Showing 1 to 25 of 63. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.